Research and Academic Institute to Account for over 1/3rd Recombinant Protein Sales: Fact.MR
Faster approval of drug delivery and increasing research to discover advanced treatment for diseases such as hemophilia is enabling recombinant protein sales
Fact.MR, Rockville MD: A report by Fact.MR on global recombinant protein market projects a steady growth through 2022 owing to the high investment in research activities associated with recombinant protein. According to the study, the investment in drug development and toxicity screening is expected to provide lucrative growth opportunities to manufactures.
Government initiatives and researches to produce pharmaceutical products and protein-based polymers for drug delivery are fuelling the demand for recombinant proteins. Research and development (R&D) activities carried out in pharmaceutical and biotechnology academic research institutes often utilize recombinant proteins, which is a key driver for the market demand.
For more insights into the Market, Request a Sample of this Report https://www.factmr.com/connectus/sample?flag=S&rep_id=186
“Rising incidence of ailments such as cardiovascular diseases, and endocrine, viral, and cancer are encouraging researchers to invest in extensive research for the utilization of recombinant protein in drug development,” says the Fact.MR analyst.
- United States is expected to reach valuation of over US$ 150 Mn by 2022-end
- Brazil is expected to witness a sluggish growth through 2021
- Toxicity screening and drug discovery is estimated to have the fastest growth during the forecast period
- Academic & research institutes to remain the most lucrative end-users
- Sales of chemokines to register fastest expansion through 2022
- Application in forensic testing is expected to register the lowest CAGR by 2022-end
- Rising government initiatives and funding in R&D through pharmaceutical & biotechnology companies is fuelling demand
- High prevalence of infectious and chronic diseases is driving the demand for recombinant protein market
- Increasing focus on personalized medicine and protein therapeutics to accelerate the growth
- Declining cost of recombinant proteins and lack of awareness is likely to hinder the growth
- Financial & technical barriers to act as a restraint for recombinant protein market
Discover more about the recombinant protein market with 105 figures, 281 data tables and the table of contents. https://www.factmr.com/report/186/recombinant-protein-market
Abcam PLC. A.M.S Biotechnology Limited, Bio-Rad Laboratories Inc., BPS Bioscience Inc., PerkinElemer Inc., Crown BioScience Inc., GenScript Corporation, and Thermo Fisher Scientific Inc. among others are some of the leading players profiled by Fact.MR.
In June 2020, PDS Biotech announced preclinical data for PDS0203, a t-cell activating recombinant protein vaccine against covid-19. The Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting T-cell responses and potent neutralizing antibody responses within 14 days of vaccination.
Likewise, on 18th June 2020, Lonza expanded its cell culture media portfolio with the addition of the GSv9™ Media, providing a fully integrated solution specifically designed to optimize recombinant protein production using Lonza’s GS Gene Expression System®. The new chemical formula, animal-component free media and feeds are intended to be user-friendly, highly robust and has greater consistency. Hence, biopharmaceutical manufacturers can more easily develop streamlined and scalable bio production processes.
Also in June 2019, The Skin Cancer Foundation, the leading nonprofit organization focused on public and professional education, launched a campaign called The Big See®. The multiyear public service campaign, which was seen nationwide, to empower people to take a proactive approach to skin cancer detection was pro-bono.
More Insights on the Recombinant protein Market
In its latest insights, Fact.MR gives an incisive coverage on global recombinant protein market through 2021 and beyond. In order to gain perspective, ongoing trends, challenges and opportunities expected to prevail the market in upcoming years, the market is segmented on the basis of product type (immune checkpoint regulators, chemokine, cytokines, colony stimulating factors, hormones, enzymes & inhibitors and others), end-user (biopharmaceutical companies, contract research organizations, academic & research institutes, forensic science laboratories, food & beverage companies, diagnostic centers, and others) and application (drug discovery & development, basic research, toxicity screening, biopharmaceutical production, drug screening, tissue engineering, and forensic testing) across key regions with detailed competitive landscape.
Request more information about Report Methodology
Explore Fact.MR’s Coverage on the Healthcare Domain
Bilateral Osteoarthritis Treatment Market: A recent study by Fact.MR on the bilateral osteoarthritis treatment market offers an unbiased analysis on the opportunities and trends through 2021 and beyond. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the challenges, restraints, and opportunities for key market players along with key stakeholders and emerging players.
Tuberculosis biomarkers Market: Fact.MR gives a detailed assessment of tuberculosis biomarkers market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.
Large macrolide drugs Market: Fact.MR delivers an in-depth analysis on global large macrolide drugs market with the strategies and competitive landscape through 2021 and beyond. The key players’ market share data provided by the report given you a detailed insights on the shortcomings and forthcomings of the market for the forecast period.
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.